Chiesi Group Completes Acquisition of KalVista Pharmaceuticals; Stock Delisted
KALV has more than doubled off its 52-week low of $9.83.
Summary
Chiesi Group has completed its acquisition of KalVista Pharmaceuticals for $27.00 per share in cash, resulting in KalVista's delisting from Nasdaq.
Key Events · M&A and Partnerships · KALV
-
Acquisition Completed
Chiesi Group has successfully completed its tender offer and subsequent merger to acquire KalVista Pharmaceuticals, Inc.
-
Tender Offer Results
Approximately 77.8% of KalVista's outstanding shares were validly tendered and accepted for payment at $27.00 per share, satisfying the minimum condition.
-
Cash Payout for Remaining Shares
All outstanding shares not tendered were converted into the right to receive $27.00 per share in cash.
-
Delisting from Nasdaq
As a result of the merger, KalVista's common stock has ceased trading on the Nasdaq Global Market.
Analysis · KALV · Life Sciences
This filing confirms the successful completion of Chiesi Group's tender offer and subsequent merger, making KalVista Pharmaceuticals a wholly-owned subsidiary. This is a definitive, thesis-altering event as KalVista's common stock has ceased trading on the Nasdaq Global Market, providing a cash exit for shareholders at $27.00 per share.
At the time of this filing, KALV was trading at $27.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $9.83 to $27.00. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.